MRNA logo Moderna +
Moderna
+

Moderna (MRNA) Business News

Track Moderna in real time with a live news feed covering Moderna stock news, official press releases, company announcements, and an archive of historical Moderna news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
1:01 PM | Thursday | Oct 8, 2026 Seeking Alpha

Arbutus Biopharma: $230M Buyback And Moderna Cash De-Risk The Path To A Potential HBV Cure

News Thumbnail
9:46 AM | Thursday | Oct 8, 2026 Zacks Investment Research

Moderna's Nasdaq-100 Entry: What Does It Mean for the Stock?

News Thumbnail
7:30 AM | Thursday | Oct 8, 2026 247 Wallst

3 Stocks That Have More Than Doubled the S&P 500’s Return This Year

News Thumbnail
9:46 AM | Thursday | Oct 8, 2026 Zacks Investment Research

Moderna's Nasdaq-100 Entry: What Does It Mean for the Stock?

News Thumbnail
7:30 AM | Thursday | Oct 8, 2026 247 Wallst

3 Stocks That Have More Than Doubled the S&P 500’s Return This Year

News Thumbnail
8:30 AM | Wednesday | Oct 7, 2026 Business Wire

Tempus Announces Multi-Year Collaboration with Moderna and Merck

News Thumbnail
9:56 AM | Tuesday | Oct 6, 2026 24/7 Wall Street

Novavax Pulls Back From Plague-Scare Spike as Officials Call Risk Low; Moderna Nudges Higher, Pfizer Inches Higher

News Thumbnail
3:02 PM | Monday | Oct 5, 2026 24/7 Wall Street

Novavax Soars 22% as Sanofi Carries Nuvaxovid Into Vaccination Season; Moderna Climbs 8%, BioNTech Ticks Up

News Thumbnail
2:47 PM | Monday | Oct 5, 2026 24/7 Wall Street

Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips

News Thumbnail
9:10 AM | Friday | Oct 2, 2026 Schaeffers Research

Dow Futures Chart Over 400 Points Higher After Weak Jobs Data

News Thumbnail
7:05 AM | Friday | Oct 2, 2026 Seeking Alpha

Wall Street Breakfast Podcast: No Sprint For Nike Yet

News Thumbnail
6:09 AM | Friday | Oct 2, 2026 Invezz

Moderna stock rises 2% on Nasdaq 100 entry but this analyst says sell

News Thumbnail
5:51 AM | Friday | Oct 2, 2026 Barrons

Nike, ON Semi, Moderna, and More Stocks That Explain Today's Market

News Thumbnail

Arbutus Biopharma: $230M Buyback And Moderna Cash De-Risk The Path To A Potential HBV Cure

Seeking Alpha

1:01 PM | Thursday | Oct 8, 2026

news photo
Loading...

Arbutus Biopharma is rated Buy, leveraging a $179.1M Moderna settlement and a 46M share buyback to enhance per-share value. Imdusiran, ABUS's RNAi asset for chronic hepatitis B, targets a functional cure and could generate $1.59–$2.39B in peak annual revenue if successful.
Current valuation ($4.50/share) slightly exceeds risk-adjusted fair value ($3.91), with upside tied to positive Phase 2b/3 Imdusiran results.

Read full article redirect
1:01 PM | Thursday | Oct 8, 2026

Arbutus Biopharma: $230M Buyback And Moderna Cash De-Risk The Path To A Potential HBV Cure

Seeking Alpha

Arbutus Biopharma is rated Buy, leveraging a $179.1M Moderna settlement and a 46M share buyback to enhance per-share value. Imdusiran, ABUS's RNAi asset for chronic hepatitis B, targets a functional cure and could generate $1.59–$2.39B in peak annual revenue if successful.
Current valuation ($4.50/share) slightly exceeds risk-adjusted fair value ($3.91), with upside tied to positive Phase 2b/3 Imdusiran results.

Read full article arrow
News Thumbnail
9:46 AM | Thursday | Oct 8, 2026

Moderna's Nasdaq-100 Entry: What Does It Mean for the Stock?

Zacks Investment Research

MRNA's Nasdaq-100 entry follows a 566% stock surge and stronger cancer therapy prospects, potentially boosting demand from index-tracking funds.

Read full article arrow
News Thumbnail
7:30 AM | Thursday | Oct 8, 2026

3 Stocks That Have More Than Doubled the S&P 500’s Return This Year

247 Wallst

Three stocks left the S&P 500's 2025 return in the dust, but gains that large raise one uncomfortable question: is the opportunity already gone, or does one of them still have a real runway ahead?

Read full article arrow
News Thumbnail
9:46 AM | Thursday | Oct 8, 2026

Moderna's Nasdaq-100 Entry: What Does It Mean for the Stock?

Zacks Investment Research

MRNA's Nasdaq-100 entry follows a 566% stock surge and stronger cancer therapy prospects, potentially boosting demand from index-tracking funds.

Read full article arrow
News Thumbnail
7:30 AM | Thursday | Oct 8, 2026

3 Stocks That Have More Than Doubled the S&P 500’s Return This Year

247 Wallst

Three stocks left the S&P 500's 2025 return in the dust, but gains that large raise one uncomfortable question: is the opportunity already gone, or does one of them still have a real runway ahead?

Read full article arrow
News Thumbnail
8:30 AM | Wednesday | Oct 7, 2026

Tempus Announces Multi-Year Collaboration with Moderna and Merck

Business Wire

CHICAGO--(BUSINESS WIRE)--Tempus (NASDAQ: TEM) today announced an expanded, multi-year collaboration to support the potential commercialization of intismeran autogene (V940/mRNA-4157), a novel, potential first-in-class individualized neoantigen therapy (INT) being evaluated in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with completely resected stage IIB-IV melanoma and other cancer types. Intismeran autogene is jointly developed by Moderna and Merck, know.

Read full article arrow
News Thumbnail
9:56 AM | Tuesday | Oct 6, 2026

Novavax Pulls Back From Plague-Scare Spike as Officials Call Risk Low; Moderna Nudges Higher, Pfizer Inches Higher

24/7 Wall Street

A plague headline out of Siberia lifted vaccine stocks, and the agencies closest to the case have since described the risk as low.

Read full article arrow
News Thumbnail
3:02 PM | Monday | Oct 5, 2026

Novavax Soars 22% as Sanofi Carries Nuvaxovid Into Vaccination Season; Moderna Climbs 8%, BioNTech Ticks Up

24/7 Wall Street

Sanofi is carrying the Nuvaxovid COVID-19 shot into the fall vaccination season, and buyers are rewarding shares of licensor Novavax (NASDAQ:NVAX) far more heavily than the rest of biotech. Novavax stock has rose 17% during afternoon trading, reaching $12.

Read full article arrow
News Thumbnail
2:47 PM | Monday | Oct 5, 2026

Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips

24/7 Wall Street

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are trading as though the company's messenger RNA (mRNA) cancer vaccine has already cleared its final test, even though the complete Phase 3 dataset has yet to be presented publicly.

Read full article arrow
News Thumbnail
9:10 AM | Friday | Oct 2, 2026

Dow Futures Chart Over 400 Points Higher After Weak Jobs Data

Schaeffers Research

Stock futures are moving notably higher as investors digest nonfarm payrolls and cooling yields

Read full article arrow
News Thumbnail
7:05 AM | Friday | Oct 2, 2026

Wall Street Breakfast Podcast: No Sprint For Nike Yet

Seeking Alpha

Nike (NKE) faces persistent headwinds, with Q1 sales down 4% and China revenue plunging 22% year-over-year. Moderna (MRNA) will join the Nasdaq-100 replacing Warner Bros Discovery (WBD).

Read full article arrow
News Thumbnail
6:09 AM | Friday | Oct 2, 2026

Moderna stock rises 2% on Nasdaq 100 entry but this analyst says sell

Invezz

Moderna stock (NASDAQ: MRNA) rose more than 2% in early premarket trading on Friday after Nasdaq said the biotech company will join the Nasdaq-100 next week, creating new demand from index-tracking funds. The move follows a spectacular 2026 rally that has pushed Moderna more than 500% higher and transformed it from a post-pandemic recovery story into an oncology bet.

Read full article arrow
News Thumbnail
5:51 AM | Friday | Oct 2, 2026

Nike, ON Semi, Moderna, and More Stocks That Explain Today's Market

Barrons

Nike slumps after the retailer misses analysts' first-quarter earnings target and issues downbeat full-year guidance.

Read full article arrow
News Thumbnail